Natalie Pompilio

For the past 3 decades, Carlos L. Arteaga, MD, has focused his research on drug-resistant breast cancers, seeking to identify the causes of resistance and proposing combination therapies to beat that resistance.

“I don’t intend to rest on any laurels as thereis still much more to be done.”

As CEO of the American Society of Clinical Oncology, Clifford A. Hudis, MD, is always on the go—and not just between his home in New York and ASCO headquarters in Virginia.

The NCCN is working to develop modified guidelines for specific regions that offer less-costly and less–technologically intensive cancer treatment alternatives.

When the FDA approved its first biosimilar drug in 2015—filgrastim-sndz, for compromised white blood cell count—there was talk of the benefits of competition in the pharma industry; increased access to medications for patients; and, of course, the all-around savings. Four years later, those benefits haven’t been fully realized,

With hugely destructive storms now almost routine—3 of the 5 costliest hurricanes on record occurred in 2017—the secret to practice readiness is constant review and analysis.

An increasing number of oncologists are choosing to specialize, affecting how patient care is delivered and the futures of small practices and large cancer clinics.

The Oncology Care Model is a patient-centric program that the Centers for Medicare & Medicaid Services says will allow for “better care, smarter spending, and healthier people.”